-
Approved production of Zhifei biological typhoid Vi polysaccharide vaccine
Time of Update: 2020-04-03
According to the information on June 18 on the website of the State Food and Drug Administration (CFDA), the production approval of typhoid Vi polysaccharide vaccine declared by Beijing green bamboo b
-
Silitan, a new antihypertensive drug of xinlitai, plans to carry out overseas registration and clinical work
Time of Update: 2020-04-03
Xinlitai (Ye Yuxiang, general manager, said at the performance briefing today that the company's new product, xinlitan (alisartan ester tablets), is a global innovative product At present, it has obta
-
Shutai snake venom class I new drug "clotting factor X activator for injection" is expected to enter the second phase of clinical practice this year
Time of Update: 2020-04-03
Shutai Shenzhong new drug "clotting factor X activator for injection" is in the second phase of clinical application, and is expected to enter the second phase of clinical application this year "Clott
-
Clinical approval of pegylated recombinant human interferon α 2B injection in Anke
Time of Update: 2020-04-03
On the evening of May 22, an kebio announced that the company's self-developed and characteristic pegylated recombinant human interferon α 2B injection was approved by the State Food and Drug Administ
-
"Microecological new drug project" of Donghai pharmaceutical won the first prize of Qingdao technology invention
Time of Update: 2020-04-03
Qingdao Donghai Pharmaceutical Co., Ltd has experienced 8 years of painstaking research and development of a series of micro ecological new drug projects Recently, it has successfully realized industr
-
Lenalidomide preparation of Shuanglu pharmaceutical industry has been applied for production
Time of Update: 2020-04-03
Shuanglu Pharmaceutical (002038 SZ) said on the interactive platform that lenalidomide preparation had recently been declared for production According to the website of the State Food and Drug Adminis
-
Fosun medicine transfers two new drugs of type II diabetes and tumor to sellas
Time of Update: 2020-04-03
As a leading pharmaceutical listed company in China, Fosun Pharmaceutical has made important progress in R & D and innovation On October 23, 2013, Chongqing fuchuang Pharmaceutical Research Co., Ltd (
-
Review of new approvals for the first quarter of 2015
Time of Update: 2020-04-03
The approvals issued so far this month include 198 chemicals, 386 traditional Chinese medicines and 13 biological products This month, a large number of TCM approvals were issued, all of which were non new In addition, the editor analyzed the differences between the drugs approved by CFDA in the first quarter of this year and last year Is the approval speed faster than last year?
-
Huahai Pharmaceutical Co., Ltd.'s withdrawal of 8 drug applications
Time of Update: 2020-04-03
A notice issued by the General Administration of drugs on the 26th once again pushed Huahai Pharmaceutical (600521) to the forefront of the wave Huahai pharmaceutical shares fell 4.41% on the 27th In
-
Sichuan chuanshegan flavone capsule and Ranjiangduoji capsule obtained the production approval
Time of Update: 2020-04-03
Recently, chuanshegan flavone capsule and Ranjiangduoji capsule, two kinds of traditional Chinese medicine, have been approved by the State Administration, breaking through the situation that no new t
-
Adenosylmethionine succinate, a new hepatobiliary drug from Zhenyuan, Zhejiang Province, has entered the final approval stage
Time of Update: 2020-04-03
This means that the drug has passed the technical review and production site inspection and entered the final approval stage Zhejiang Zhenyuan is expected to obtain the product production approval doc
-
Huadong Pharmaceutical Group 3.1 antifungal drug kapofungin acetate applied for production accepted
Time of Update: 2020-04-03
According to the information on April 3 on the website of the State Food and Drug Administration (CFDA), the application for the production of 3.1 antifungal drug kapofen acetate was accepted Accordin
-
Another new indication of nerve growth factor in Shandong unnamed mice is approved
Time of Update: 2020-04-03
Drug clinical trial approval document (SZ: 002581): Notice on obtaining drug clinical trial approval document Shandong Weiming biomedical Co., Ltd., a wholly-owned subsidiary of Shandong Weiming biome
-
Tonghua Dongbao third generation insulin, insulin glargine, received the information of hair and tonic
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on April 4, the third generation of Tonghua Dongbao insulin "insulin glargine" and "insulin glargine injection" reported clini
-
New drug research and development progress disclosed by Northeast Pharmaceutical
Time of Update: 2020-04-03
Zhang Zhengwei, financial director of Northeast Pharmaceutical, stressed in the dingzeng roadshow that the company is now gradually completing the transformation from API to pharmaceutical industry ch
-
The unveiling ceremony of the State Key Laboratory of innovative drugs and efficient energy saving pharmaceutical equipment was held in Jiangzhong group
Time of Update: 2020-04-03
On the morning of November 28, the unveiling ceremony of the State Key Laboratory of innovative drugs and efficient energy saving and consumption reducing pharmaceutical equipment was held in Jiangzho
-
Brief introduction of drugs accepted by CDE in March 2014
Time of Update: 2020-04-03
In March 2014, the CDE received 745 drug applications, an increase of nearly 40% over February Among them, 212 new drug applications, 193 copy applications and 68 import applications all increased to
-
[in depth inventory] up to now, there are only 10 kinds of domestic monoclonal antibodies approved by CFDA for listing
Time of Update: 2020-04-03
In 1986, OKT3, the world's first monoclonal antibody drug for the treatment of rejection in organ transplantation, was approved by the US FDA, which started the development of monoclonal antibody drug
-
Guizhou bailing anti hepatitis a new drug tifentai Y101 obtained clinical approval
Time of Update: 2020-04-03
Tefentai tablet is a kind of new chemical medicine against hepatitis B, and it is a major new drug creation project in the 12th Five Year Plan, Guizhou bailing has undertaken a total of 30 million yua
-
Clinical approval of yizhemeb tablets
Time of Update: 2020-04-03
Approval document for clinical trials of drugs (SH: 600422): Announcement on obtaining the approval document for clinical trials of yizheimai tablets Recently, kunyao Group Co., Ltd (hereinafter refer
